Far more than, the association between CD133+ CSCs and EGFR mutation in NSCLC patients is further deserving of attention and exploration, which may provide a new therapeutic perspective on the treatment of NSCLC patients according to the expression of CD133 and the intrinsic EGFR gene status of CD133+ CSCs. Here, EGFR is linked to non-small cell lung carcinoma.